Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL

Journal of Investigative Dermatology

Volumn 122, Issue 4, 2004, Pages 1042-1049

  Klimuk, Sandra K ^a   Najar, Hossain M ^b   Semple, Sean C ^a   Aslanian, Soudabeh ^b   Dutz, Jan P ^b,c  

^a Inex Pharmaceuticals Corporation   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Skin Care Center   (Canada)

Author keywords

Adjuvant; CTL; Oligodeoxynucleotides; Skin; Tumor

Indexed keywords

ANTIGEN; OLIGONUCLEOTIDE; OVALBUMIN; PEPTIDE; POLYGUANYLIC ACID; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SKIN; TUMOR;

EID: 2342447405     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.22411.x     Document Type: Article

References (49)

1. Altman JD, Moss PA, Goulder PJ, et al: Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96, 1996
2. Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M: Cutaneous vaccination: The skin as an immunologially active tissue and the challenge of antigen delivery. J Control Release 66:199-214, 2000
3. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167:4878-4886, 2001
4. Ban E, Dupre L, Hermann E, et al: CpG motifs induce Langerhans cell migration in vivo. Int Immunol 12:737-745, 2000
5. Bangham CRM, McMichael AJ: Teen immunity to viruses. In: Feldmann M, Lamb J, Owen MJ (eds). T cells. New York: John Wiley and Sons, 1989; p 281-310
6. Beignon AS, Briand JP, Muller S, Partidos CD: Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology 102:344-351, 2001
7. Bergstresser PR, Fletcher CR, Streilein JW: Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties. J Invest Dermatol 74:77-80, 1980
8. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365, 1994
9. Bos JD, Meinardi MM: The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9:165-169, 2000
10. Bour H, Peyron E, Gaucherand M, et al: Major histocompatibility complex class I-restricted CD8+ T cells and class II-restricted CD4+ T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur J Immunol 25:3006-3010, 1995
11. Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell- associated antigen in vivo. J Exp Med 171:377-387, 1990
12. Celluzzi CM, Falo LD Jr. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J Invest Dermatol 108:716-720, 1997
13. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623-1631, 1997
14. Davila E, Velez MG, Heppelmann CJ, Celis E: Creating space: An antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood 100:2537-2545, 2002
15. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL: Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159:237-243, 2001
16. Glenn GM, Rao M, Matyas GR, Alving CR: Skin immunization made possible by cholera toxin. Nature 391:851, 1998a
17. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR: Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 161:3211-3214, 1998b
18. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR: Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 67:1100-1106, 1999
19. Hammond SA, Walwender D, Alving CR, Glenn GM: Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 19:2701-2707, 2001
20. Hemmi H, Takeuchi O, Kawai T, et al: A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745, 2000
21. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC: Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161:3042-3049, 1998
22. Jakob T, Walker PS, Krieg AM, von Stebut E, Udey MC, Vogel JC: Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: Implications for the augmentation of Th1 responses. Int Arch Allergy Immunol 118:457-461, 1999
23. Kahlon R, Hu Y, Orteu C, Kifayet A, Trudeau J, Tan R, Dutz J: Optimization of epicutaneous immunization for the induction of CTL. Vaccine 21:2890-2899, 2003
24. Klinman DM, Yamshchikov G, Ishigatsubo Y: Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158:3635-3639, 1997
25. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760, 2002
26. Krieg AM, Yi AK, Matson S, et al: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549, 1995
27. Krug A, Rothenfusser S, Hornung V, et al: Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31:2154-2163, 2001
28. Matioubian M, Concepcion RJ, Ahmed R: CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68:8056-8063, 1994
29. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P: CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 166:1212-1218, 2002
30. Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM, Zavala F: Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Meth 181:45-54, 1995
31. Miyata M, Kobayashi H, Sasajima T, Sato Y, Kasukawa R: Unmethylated oligo-DNA containing CpG motifs aggravates collagen-induced arthritis in mice. Arthritis Rheum 43:2578-2582, 2000
32. Moore MW, Carbone FR, Bevan MJ: Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777-785, 1988
33. Mui B, Raney SG, Sample SC, Hope MJ: Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther 298:1185-1192, 2001
34. Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M: Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J Invest Dermatol 109:175-182, 1997
35. Noonberg SB, Garovoy MR, Hunt CA: Characteristics of oligonucleotide uptake in human keratinocyte cultures. J Invest Dermatol 101:727-731, 1993
36. Partidos CD, Beignon AS, Semetey V, Briand JP, Muller S: The bare skin and the nose as non-invasive routes for administering peptide vaccines. Vaccine 19:2708-2715, 2001
37. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ: Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 158:834-841, 1997
38. Romani N, Koide S, Crowley M, et al: Presentation of exogenous protein antigens by dendritic cells to T cell clones. Infact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 169:1169-1178, 1989
39. Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG: Exact prediction of a natural T cell epitope. Eur J Immunol 21:2891-2894, 1991
40. Saloga J, Renz H, Larsen GL, Gelfand EW: Increased airways responsiveness in mice depends on local challenge with antigen. Am J Respir Crit Care Med 149:65-70, 1994
41. Sato Y, Roman M, Tighe H, et al: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352-354, 1996
42. Scharton-Kersten T, Yu J, Vassell R, O'Hagan D, Alving CR, Glenn GM: Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 68:5306-5313, 2000
43. Schuler-Thurner B, Schultz ES, Berger TG, et al: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279-1288, 2002
44. Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M: Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci USA 97:371-376, 2000
45. Singer AJ, Shallat J, Valentine SM, Doyle L, Sayage V, Thode HC Jr. Cutaneous tape stripping to accelerate the anesthetic effects of EMLA cream: A randomized, controlled trial. Acad Emerg Med 5:1051-1056, 1998
46. Sparwasser T, Hultner L, Koch ES, Luz A, Lipford GB, Wagner H: Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol 162:2368-2374, 1999
47. Steinman RM, Pope M: Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519-1526, 2002
48. Udaka K, Wiesmuller KH, Kienle S, Jung G, Walden P: Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J Immunol 157:670-878, 1996
49. Vabulas RM, Pircher H, Lipford GB, Hacker H, Wagner H: CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol 164:2372-2378, 2000